ReGenTree begins ARISE-3 trial of RGN-259 eye drops for dry eye syndrome

ReGenTree has initiated a phase 3 clinical trial, called ARISE-3, to evaluate the safety and efficacy of 0.1% RGN-259 eye drops for the treatment of ... Read More